CoChat

Combined Serological, Genetic, and Inflammatory Markers Differentiate Non-IBD, Crohnʼs Disease, and Ulcerative Colitis Patients

Open access
Plevy, Scott, Silverberg, Mark S., Lockton, Steve, Stockfisch, Tom, Croner, Lisa, Stachelski, Jordan, Brown, Michelle, Triggs, Cheryl, Chuang, Emil, Princen, Fred, Singh, Sharat · 2013 · Inflammatory Bowel Diseases
Cited by 128

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Previous studies have demonstrated that serological markers can assist in diagnosing inflammatory bowel disease (IBD). In this study, we aim to build a diagnostic tool incorporating serological markers, genetic variants, and markers of inflammation into a computational algorithm to examine patterns of combinations of markers to (1) identify patients with IBD and (2) differentiate patients with Crohn's disease (CD) from ulcerative colitis (UC). METHODS: In this cross-sectional study, patient blood samples from 572 CD, 328 UC, 437 non-IBD controls, and 183 healthy controls from academic and community centers were analyzed for 17 markers: 8 serological markers (ASCA-IgA, ASCA-IgG, ANCA, pANCA, OmpC, CBir1, A4-Fla2, and FlaX), 4 genetic markers (ATG16L1, NKX2-3, ECM1, and STAT3), and 5 inflammatory markers (CRP, SAA, ICAM-1, VCAM-1, and VEGF). A diagnostic Random Forest algorithm was constructed to classify IBD, CD, and UC. RESULTS: Receiver operating characteristic analysis compared the diagnostic accuracy of using a panel of serological markers only (ASCA-IgA, ASCA-IgG, ANCA, pANCA, OmpC, and CBir1) versus using a marker panel that in addition to the serological markers mentioned above also included gene variants, inflammatory markers, and 2 additional serological markers (A4-Fla2 and FlaX). The extended marker panel increased the IBD versus non-IBD discrimination area under the curve from 0.80 (95% confidence interval [CI], ±0.05) to 0.87 (95% CI, ±0.04; P < 0.001). The CD versus UC discrimination increased from 0.78 (95% CI, ±0.06) to 0.93 (95% CI, ±0.04; P < 0.001). CONCLUSIONS: Incorporating a combination of serological, genetic, and inflammation markers into a diagnostic algorithm improved the accuracy of identifying IBD and differentiating CD from UC versus using serological markers alone.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/mib.0b013e318280b19e

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 128

Metadata

Authors
Plevy, S., Silverberg, M. S., Lockton, S., Stockfisch, T., Croner, L., Stachelski, J., Brown, M., Triggs, C., Chuang, E., Princen, F., & Singh, S.
Venue
Inflammatory Bowel Diseases
Published
2013-05
Volume
19
Issue
6
Pages
1139-1148
ISSN
1078-0998 (ISSN-L)
OpenAlex
W2006868978
Cited by
128
References
4
FWCI
7.08
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Combined Serological, Genetic, and Inflammatory Markers Differentiate Non-IBD, Crohnʼs Disease, and Ulcerative Colitis Patients. https://app.cochat.ai/papers/10.1097/mib.0b013e318280b19e
The paper
Plevy, S., Silverberg, M. S., Lockton, S., Stockfisch, T., Croner, L., Stachelski, J., Brown, M., Triggs, C., Chuang, E., Princen, F., & Singh, S. (2013). Combined Serological, Genetic, and Inflammatory Markers Differentiate Non-IBD, Crohnʼs Disease, and Ulcerative Colitis Patients. Inflammatory Bowel Diseases. https://doi.org/10.1097/mib.0b013e318280b19e

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.